A Prospective, Open-Label Study to Evaluate Dual-Modality Treatment With Deoxycholic Acid (ATX-101) and Hyaluronic Acid (VYC-20L) for Overall Improvement in Jawline Contour
Abstract Background A poorly defined jawline and blunting of the submental angle by excess submental fat (SMF) contribute to the loss of jawline contour. The injectable adipocytolytic agent ATX-101 reduces SMF, and the hyaluronic acid filler VYC-20L restores facial volume in the chin and jaw. Objectives The objective of this study was to evaluate the benefits of ATX-101 followed by VYC-20L for improving overall jawline contour and definition. Methods In this Phase 4, prospective, open-label, multicenter trial, participants received 1 to 6 ATX-101 treatments (8 weeks apart), followed by VYC-20L with optional VYC-20L touch-up after 14 days. The primary endpoint was Allergan Loss of Jawline Definition Scale (ALJDS) responder rate (proportion achieving ≥1-point improvement from baseline in investigator-assessed ALJDS score 4 weeks after final VYC-20L treatment). Secondary and exploratory endpoints included clinician- and participant-assessed measures of jawline definition, satisfaction, skin laxity, and SMF. Treatment-emergent adverse events (TEAEs) were monitored. Results Overall, 53 adults were enrolled and treated. Among 42 evaluable participants, the ALJDS responder rate was 92.9% (95% CI, 80.5-98.5). Consistent improvement across a range of clinician- and participant-assessed scales was achieved, including improvements in SMF Rating Scale score, Submental Skin Laxity Grade, and Global Aesthetic Improvement Scale score. Improvements in FACE-Q Satisfaction with Lower Face and Jawline and Appraisal of Area Under Chin indicated high levels of patient satisfaction. All participants experienced at least 1 TEAE; the majority of TEAEs were moderate in severity. Conclusions Sequential treatment with ATX-101 and VYC-20L may be effective for improving overall jawline contour and definition, with an acceptable safety profile. Level of Evidence: 2 (Therapeutic)
Authors
- Lucille Alker
- Mark W. Ashton (ORCID: https://orcid.org/0000-0002-5104-480X)
- Michael Silberberg
- Greg Goodman (ORCID: https://orcid.org/0000-0003-4089-9690)
- Natasha Cook
- Stefania Roberts (ORCID: https://orcid.org/0000-0001-7994-1812)
Institutions
- The University of Melbourne (AU)
- AbbVie (United States) (US)
- St Vincent's Hospital Sydney (AU)
- AbbVie (Ireland) (IE)
- St Vincent’s Private Hospital Sydney (AU)
- Allergan (United Kingdom) (GB)
- Sextures Institute (AU)
- Allergan (United States) (US)
- AbbVie (United Kingdom) (GB)
- Monash University (AU)
Publication Details
- Journal
- Aesthetic Surgery Journal Open Forum
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/asjof/ojaf081
- Primary Topic
- Bee Products Chemical Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Allergan